Michael Gratch (@mbgratch) header
Michael Gratch (@mbgratch) profile picture

Founder & CEO, Flow Therapy. Building the national platform for Counterpulsation Therapy. The physiological category alongside meds and procedures.

Fort Worth, TX
Joined April 2009
Photo by Michael Gratch (@mbgratch)Photo by Michael Gratch (@mbgratch)Photo by Michael Gratch (@mbgratch)Photo by Michael Gratch (@mbgratch)
There’s a gap in cardiology that deserves a brighter light. Millions of symptomatic patients are waiting for a therapy that works alongside their meds and procedures, not after. A real next step, way before the thought of “nothing else.” This is who we built Flow Therapy for.
1
3
2,159
🫀⚠️ We fix the arteries.
 But what if the problem isn’t just in the lumen of the main coronary arteries? This Lancet study goes straight at a blind spot we all know exists—but rarely quantify. 🧠 The setup 1003 real-world patients undergoing invasive angiography + full physiology (FFR, CFR, IMR) So not theory. 👉 actual coronary physiology in practice 🔍 The uncomfortable finding 👉 Coronary microvascular dysfunction (CMD) in ~16% of patients And not just in “normal coronaries”: - 21.5% WITH obstructive CAD - 9.3% WITHOUT obstructive CAD Translation 👉 Microvascular disease is NOT a niche problem 👉 It is embedded within “classic CAD” 📉 Outcomes (this is where it gets real) At ~2 years: 👉 18.8% events with CMD 👉 10.5% without 👉 HR ~1.9 And here’s the kicker: In patients WITHOUT obstructive CAD: 👉 HR ~3.45 🧠 Translation (again, because this matters) You can have: 👉 “normal” coronaries (by FFR) 👉 no revascularization And still: 👉 a 3x higher risk ⚠️ The paradigm problem Our entire workflow is built around: 👉 stenosis 👉 FFR 👉 revascularization But this paper shows: 👉 fixing epicardial disease does NOT normalize risk 🧬 Why? Because CMD reflects: - microvascular dysfunction - endothelial dysfunction - inflammation - diffuse myocardial injury Not a plumbing problem 👉 a biological one 🧠 My take This paper doesn’t just add information. It exposes a structural limitation: 👉 we are solving the visible part of the disease And missing: 👉 the microcirculation 👉 the diffuse component 👉 the residual risk That is the underlying atherosclerotic/metabolic/inflammatory milieu. ⚡ The real implication If you only measure: 👉 stenosis 👉 FFR You are ignoring: 👉 a major determinant of outcomes 🚨 Bottom line CAD ≠ epicardial stenosis Ischemia ≠ FFR alone 👉 Coronary disease is multi-level 👉 And the microcirculation is not optional Final uncomfortable thought We’ve optimized PCI. We’ve optimized stents. We’ve optimized FFR. But: 👉 we still don’t systematically measure what happens beyond them #Cardiology #CMD #Microcirculation #FFR #CardiacRisk #PrecisionMedicine
7
17
55
3,693
A note on language. For decades, cardiology has known this therapy as EECP. The evidence base was built under that name, and the clinicians who championed it deserve real credit. But the name carried the confines of an earlier era: limited access, uneven awareness.
🤖 Made with AI
1
1
35
We say Counterpulsation Therapy now. Modern delivery. Built to bring it back into the conversation, and within reach of the patients who benefit. The therapy hasn’t changed. The difference is how well we understand it, and how access is changing.
1
24
Last week, some of the leading voices in cardiology discussed #Counterpulsation Therapy and the patients with persistent symptoms who benefit from a real next step. Grateful for the conversation w @CMichaelGibson, @potluri70, @TonyDasMD, @ThuyPhamDO, Dr. Mo. More to come. #EECP
2
1
4
5,670
Walking the Gainesville site today. The next clinic is taking shape. Partnership with Northeast Georgia Health System. Opening this summer. More patients with a real next step. The build continues.
2
178
At Flow Therapy, we’re building the national platform to advance that work. Clinics expanding across Texas, North Carolina, and Georgia. 1,000+ referring cardiologists. A clinical pathway used by service line leaders at major health systems. A patient population being seen.
1
78
If you’re a clinician with patients living in that gap, this account will be a place to follow the work. If you’re a patient or family member still searching for a real next step, there is one. And there’s more to come.
57
Which is why #EECP has been game changing for people with #LongCovid who can access it. (Thankfully me)
Blood vessel wall (endothelial) inflammation as a key to multi-organ complications of Covid and #LongCovid @ScienceMagazine w/ @ScienceVisuals science.org/doi/10.1126/scie…
4
20
4
84
12,393
A study on #COVID19 patients with + w/out #cvCAD showed symptom improvement after 15-35 hrs of EECP therapy. This study will be presented at @ACCinTouch #CVSummit virtually this weekend Feb. 16-19 ❕ bit.ly/34XJb44 @ScienceMagazine
#TreatLongCovid has really been on my mind recently & thinking about what helps #PASC patients: - Pacing & energy conservation (yes, physiotherapists teach them this. But NOT graded exercise) - EECP (such as at @FlowTherapyEECP) - Mast cell protocol - POTS protocol What else?
4
3
1
17
Optimal Medical Therapy as First‑Line Therapy for Chronic Coronary Syndromes: Lessons from COURAGE, BARI 2D, FAME 2, and ISCHEMIA pubmed.ncbi.nlm.nih.gov/3476… ; bit.ly/3nr6dqQ by @DavidLBrownMD
5
1
12
#INOCA affects a significant proportion of the population with an estimated 3-4 million people thought to have undiagnosed INOCA in the US. But did you know that INOCA is more common in women?
2
2